Immunovaccine Launches DPX-NEO Program to Develop Patient-Specific Neoepitope Immunotherapies

HALIFAX, NOVA SCOTIA (Marketwired May 5, 2016) Immunovaccine Inc. ( Immunovaccine or the company ) (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced the launch of its DPX-NEO program to develop neoepitope immunotherapies to further expand the immuno-oncology applications for its DepoVax™-based vaccines. As its first official partnership for this program, Immunovaccine will collaborate with experts in this field at UConn Health on a preclinical study to evaluate the immunologic and anti-tumor activity of patient-specific neoepitopes. Epitopes are the The post Immunovaccine Launches DPX-NEO Program to Develop Patient-Specific Neoepitope Immunotherapies appeared first on Public Wire.
http://bit.ly/1OpqKAQ

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: